SCHEMBL867348

SCHEMBL867348

CC(NS(=O)(=O)c1ccc(N)c2ccccc12)C(=O)O

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADAMTS4 O75173 1/20 0.51
NSD2 O96028 6/20 0.46
ALOX5AP P20292 1/20 0.45
FEN1 P39748 1/20 0.45
SLC1A3 P43003 2/20 0.45
SLC1A2 P43004 2/20 0.45
SLC1A1 P43005 2/20 0.45
HTT P42858 1/20 0.43
MMP1 P03956 1/20 0.43
MMP2 P08253 1/20 0.43
MMP3 P08254 1/20 0.43
MMP7 P09237 1/20 0.43
MMP9 P14780 1/20 0.43
MMP13 P45452 1/20 0.43
TTR P02766 1/20 0.41
KDM4E B2RXH2 1/20 0.40
ALDH1A1 P00352 1/20 0.40
HPGD P15428 1/20 0.40
CASP1 P29466 1/20 0.40
CASP7 P55210 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5148149 0.85 SLC1A3 (0.51) ADAMTS4NSD2SLC1A3SLC1A2SLC1A1
SCHEMBL3813105 0.83 ALDH1A1 (0.54) NSD2ALOX5APFEN1SLC1A3SLC1A2
SCHEMBL9670221 0.82 NSD2 (0.45) NSD2SLC1A3SLC1A2SLC1A1ALDH1A1
SCHEMBL27388236 0.82 ADAMTS4 (0.56) ADAMTS4ALOX5APFEN1SLC1A3SLC1A2
SCHEMBL5587395 0.82 SLC1A3 (0.48) ADAMTS4NSD2SLC1A3SLC1A2SLC1A1
SCHEMBL6266412 0.81 PKLR (0.50) NSD2SLC1A3SLC1A2SLC1A1MMP2
SCHEMBL5149287 0.80 MMP9 (0.44) ADAMTS4NSD2MMP2MMP9MMP13
SCHEMBL180020 0.80 NSD2 (0.45) ADAMTS4NSD2SLC1A3SLC1A2SLC1A1
SCHEMBL8842858 0.80 NSD2 (0.45) ADAMTS4NSD2SLC1A3SLC1A2SLC1A1
SCHEMBL9241852 0.79 NSD2 (0.50) NSD2TTR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 175 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114195878-A Ubiquitin mutant and preparation method and application thereof 中国人民解放军军事科学院军事医学研究院 2022-03-18 CN claimed
EP-2889370-A1 In vivo unnatural amino acid expression in the methylotrophic yeast Pichia pastoris The Scripps Research Institute (US) 2015-07-01 EP claimed
US-20140287464-A1 In Vivo Unnatural Amino Acid Expression in the Methylotrophic Yeast Pichia Pastoris SCRIPPS RESEARCH INST (US) 2014-09-25 US claimed
US-20140170704-A1 Production of Carrier-Peptide Conjugates Using Chemically Reactive Unnatural Amino Acids THE SCRIPPS RESEARCH INSTITUTE (US) 2014-06-19 US claimed
JP-2011527886-A 2011-11-10 JP claimed
US-20110014650-A1 IN VIVO UNNATURAL AMINO ACID EXPRESSION IN THE METHYLOTROPHIC YEAST PICHIA PASTORIS THE SCRIPPS RESEARCH INSTITUTE 2011-01-20 US claimed
EP-2231856-A2 IN VIVO UNNATURAL AMINO ACID EXPRESSION IN THE METHYLOTROPHIC YEAST PICHIA PASTORIS The Scripps Research Institute (US) 2010-09-29 EP claimed
US-20090197339-A1 In vivo unnatural amino acid expression in the methylotrophic yeast pichia pastoris THE SCRIPPS RESEARCH INSTITUTE (US) 2009-08-06 US claimed
WO-2009075847-A2 IN VIVO UNNATURAL AMINO ACID EXPRESSION IN THE METHYLOTROPHIC YEAST PICHIA PASTORIS THE SCRIPPS RESEARCH INSTITUTE (US) 2009-06-18 WO claimed
US-20090081669-A1 Fluorescent Assays Using Orthogonal tRNA - Aminoacyl Synthetase Pairs ENCODE BIO, INC. (US) 2009-03-26 US claimed
WO-2007090198-A2 FLUORESCENT ASSAYS USING ORTHOGONAL TRNA - AMINOACYL SYNTHETASE PAIRS ENCODE BIO, INC. (US) 2007-08-09 WO claimed
EP-4727592-A1 CONJUGATED MOLECULES Valink Therapeutics Ltd (GB) 2026-04-22 EP disclosed
EP-4725953-A1 SELF-ASSEMBLING PEPTIDES AND HYDROGELS Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2026-04-15 EP disclosed
EP-4720264-A1 AMINOACYL-TRNA SYNTHETASE SETS United Kingdom Research and Innovation (GB) 2026-04-08 EP disclosed
US-12551572-B2 Modified viral particles for gene therapy EUROPEAN MOLECULAR BIOLOGY LABORATORY (DE) 2026-02-17 US disclosed
US-5460943-A Projecting monochromatic light to a sample, measuring the fluorescence intensity emitted by 4-methylumbelliferone which is converted by the enzyme from the substrate TOSOH CORPORATION (JP) 1995-10-24 US disclosed
CN-1100200-A Capillary electrophoretic sampling device without electric discrimination CHEMSTRY INST CHINESE ACADEMY (CN) 1995-03-15 CN disclosed
EP-0521636-A1 Method of assay of enzymatic activity and apparatus therefor TOSOH CORPORATION (JP) 1993-01-07 EP disclosed
US-4540548-A Method of detecting fluorescent materials and apparatus for their detection YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) 1985-09-10 US disclosed
US-4419452-A Method of detecting fluorescent materials and apparatus for their detection YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) 1983-12-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12551572-B2 Modified viral particles for gene therapy SMCHD1, SMC1A, TIMCC ADAMTS4 4216/4885NSD2 566/4885ALOX5AP 3020/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.